Slide 1: Immunic Therapeutics
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains “forward-looking statements” that involve substantia risks and uncertainties for purposes of the safe harbor within the meaning of Section 27A of the Securities Act of 1933, as ‘amended, and Section 21 of the Securities
Slide 3: Our Vision
4 Our Vision We are developing new therapies with best-in-class potential for the treatment of chronic inflammatory and autoimmune diseases. 2 liGmmrsize nema © Immunic
Slide 4: Key Investment Highlights
Key Investment Highlights IMU-838: Successfully completed RRMS phase 2 study; phase 2 studies in three further indications ongoing IMU-935: Oral IL-17 inhibitor with substantial potential IMU-856: Novel target — potentially disease modifying for gastrointestinal disorders Three potential best- -clas
Slide 5: Leadership Team
) Leadership Team ec ompany is led by an experienced management team Renowned international board of directors Andreas Muehler, Mo, MBA cm \ f\ I) Manfred Groeppel, PhD coo & Daniel vitt, = PhD - CEO & President of Immunic bel 5 | ©immunic, inc. | 08/03/2020 = Duane Nash, Duane Mp, JD, MBA ) | Nash,
Slide 6: Development Pipeline
Development Pipeline IMU-856 a Intestinal Barrier Function Program Indication Target Preclinical Phase 1 Phase 2 Phase 3 imu-e3e Multiple Sclerosis DHODH a Ulcerative Colitis DHODH | a Crohn's Disease DHODH —SEEEee ee psc DHODH CE nn ci covip-1s* DHODH z= _= mu.9as Prova oRYt EY Orphan Al Diseases R
Slide 7: IMU-838: Next Generation DHODH Inhibitor
IMU-838: Next Generation DHODH Inhibitor Broad Therapeutic Potential Driven by Medical Needs IMU-838 is Intended to be a selective once daily medication for H Relapsing-Remitting RRMS patients with a well-balanced combination of favorable safety Multiple Sclerosis and convenience profile with robust
Slide 8: Mode of Action: DHODH Targeting Leads to Metabolic Stress in Metabolically Activated Cells
Mode of Action: DHODH Targeting Leads to Metabolic Stress in Metabolically Activated Cells Activated Lymphocyte Lymphocyte Insufficient pyrimidine Cy "recycling “Stressed” Lymphocyte IMU-838 La Disease related © activation Metabolically silent Activation of pyrimidine DHODH not de novo synthesis, im
Slide 9: IMU-838 Binds to DHODH and Inhibits DHODH
IMU-838 Binds to DHODH and Inhibits DHODH IMU-838 binds into the DHO and Ubiquinone iV IMU-838 exhibits high species selectivity, most binding pocket potent on human DHODH with ICSO of “160 nM DHODH Inhibition “sda ™ ean monkey fort cx hamter rouse Left: Baumgartner etl, Med, chem. 2006 4:1288-1267
Slide 10: Targeting Multiple Sclerosis
Slide 11: Treatment Compliance and Persistence are Important Considerations
Treatment Compliance and Persistence are Important Considerations for Life-Long Diseases such as Multiple Sclerosis (MS) MS Disease Coursel4] Preclinical | Relapsing-remitting phase phase Mt ttt t tit Clinical disability MRI activity Secondary progressive phase Brain volume i i lx? years >|<—10-15 y
Slide 12: The Global MS Drug Market
The Global MS Drug Market was 22 Billion USD in 2016 = Global market of MS drugs was USD 22 billion in 2016" = Currently approved drugs include oral and injectable drugs —Early injectables — Interferons (e.g. Rebif®, Avonex®) —Glatiramer acetate — Oral drugs —Teriflunomide — Dimethyl fumarate —S1P m
Slide 13: Current Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS)
Current Treatment of Relapsing-Remitting Multiple Sclerosis (RRMS) Escalation Treatment Approach in RRMS Base Medications ‘Treatment-naive Patients Low-to-moderate disease activity = Interferons = Glatiramer = acetate 3 3 = Dimethyl 2 3 fumarate 85 = = Teriflunomide Consider risks of prolonged immun
Slide 14: MS Therapies: Current Short-Comings
MS Therapies: Current Short-Comings Injectables: IFN-B1 and Orals: Infusions: glatiramer acetate S1Ps, fumarates natalizumab, anti-CD20s = Uncomfortable administration = Pre-testing: blood tests; = Frequent infusions (natalizumab) * Side-effects: flulike (IFNB1) EKG first -dose'monitoring ® Risk dis
Slide 15: Key Advantages of Targeting DHODH
Key Advantages of Targeting DHODH IMU-838 has shown antiviral activity which could prevent virus reactivation?! DHODH target allows selective targeting of metabolically highly activated cells!) Other DHODH inhibitors had no PML risk due to antiviral effects] Aubagio® demonstrated good activity in pr
Slide 16: MS Opportunity
MS Opportunity Aubagio® (teriflunomide) is currently the we Global Sales Aubagio® in Ms" only approved DHODH inhibitor for MS Worldwide Sales (in € 8) ® Aubagio® is indicated for the treatment of relapsing forms of MS, to include clinically isolated syndrome, a8 RRMS, and active secondary progressiv
Slide 17: IMU-838: Second Generation, Highly Selective DHODH Inhibitor
IMU-838: Second Generation, Highly Selective DHODH Inhibitor With Distinct Chemical Structure = Aubagio® hits off targets, e.g. protein kinases EGFR and teriflunomide (Aubagio®) Aurora All, leading to off-target toxicities"! = Aubagio® has a half-life of about 18 to 19 days in humans!]; wash-out we
Slide 18: Teriflunomide Has a Safety and Tolerability Profile
Teriflunomide Has a Safety and Tolerability Profile Not Expected From Selective DHODH Inhibition sy lymphocyte ine — Aubagio® 14 mg ff Aubagio® 7 mg Adverse Event (n=1002) B Headache | i ern weds 0H ALT increased poe Sess ose Mean neutrophil counts” Diarrhea = 2 as 5 B to Boas Alopecia z a 2a 20 Nau
Slide 19: Off-Target Effects: Kinase Inhibition by Teriflunomide
Off-Target Effects: Kinase Inhibition by Teriflunomide Terifiunomide trough level Teriflunomide is not purely selective for DHODH, it also _ inhibits kinases such as Aurora a PDGFR, Aurora A, FYN, LCK, JAK3, PIM and EGFR sak | > c S = Most common adverse tow = events of EGFR inhibitors: YN as skin d
Slide 20: Despite many therapies approved, there remains ample opportunity
Despite many therapies approved (and nearing approval) for relapsing forms of MS, there remains ample opportunity for a... safe oral well-tolerated moderately-effective anti-inflammatory, with neuroprotective properties beyond what would be expected by reducing inflammation.
Slide 21: IMU-838: Target Profile in Relapsing-Remitting Multiple Sclerosis
IMU-838: Target Profile in Relapsing-Remitting Multiple Sclerosis IMU-838 is Intended to be a Selective Once Daily Medication for RRMS Patients With a Well- Balanced Combination of Favorable Safety and Convenience Profile with Robust Clinical Activity For Patient For Neurologist 2 Convenient safety
Slide 22: Phase 2 Top-Line Data EMPhASIS Trial
Phase 2 Top-Line Data EMPhASIS Trial IMU-838 in Relapsing-Remitting Multiple Sclerosis (RRMS)
Slide 23: EMPhASIS: Phase 2 Study Overview in RRMS
EMPhASIS: Phase 2 Study Overview in RRMS Coordinating Investigator Robert Fox (Cleveland Clinic) a Blinded Treatment Period Population: RRMS With Relevant Disease Activity = Male or female ( 18 2 age < 55) = RRMS diagnosis (Revised McDonald criteria 2017) = Evidence of disease activity based on rela
Slide 24: EMPhASIS: Phase 2 Trial Design in RRMS
EMPhASIS: Phase 2 Trial Design in RRMS reening up to Main treatment period 28 days’ 24 week 30 mg IMU-838 — EoMT ———— 30 mg IMU-838 — 30 or 45 mg IMU-838" — EoT 45 mg IMU-838 — EoMT ————— 45 mg IMU-838 — 30 or 45 mg IMU-838® — —EoT Scr.exam. BL MRI Placebo — EoMT 30 mg IMU-838 — 30 or 45 mg IMU-838*
Slide 25: Patient Disposition and Treatment Discontinuations
Patient Disposition and Treatment Discontinuations iin Randomized Patients N=210 Well Balanced Patient Population Across N 4 Treatment Groups: wo Not Dosed 30mg 45 mg New Placebo | imu-838_|_imu-838 ex Male 33% 44% 28% Female 67% 56% 72% aN =~ I< 40 yrs. 65% 62% 65% Placebo 45 mg IMU-838 Age b40yrs.
Slide 26: Primary and Key Secondary Efficacy Endpoints
Primary and Key Secondary Efficacy Endpoints = e. ‘ Key Study Endpoints All MRI Scans Were Assessed Centrally by an Independent MRI Reading Center Only To evaluate the efficacy of IMU-838 as compared to placebo based on the cumulative number of new combined unique active lesions up to Week 24 = Prim
Slide 27: Efficacy
Slide 28: EMPhASIS Trial: Primary and Key Secondary Endpoints Met
EMPHASIS Trial NCT03846219 Primary and Key Secondary Endpoints Met With High Statistical Significance
Slide 29: Study Met Primary and Key Secondary Endpoints
Study Met Primary and Key Secondary Endpoints High Statistical Significance and Robust Results Regarding Suppression of CUA MRI Lesions Suppression of ae Analysis Set IMU-838 | Placebo CUA MRI Lesions cee IMU-838 vs. Placebo Primary 45 mg IMU-838 eee 7 : Speen? oe: PISGEB: Full Analysis Set N=69 62%
Slide 30: Study Meets All Primary and Key Secondary Endpoints
Study Meets All Primary and Key Secondary Endpoints % of placebo 120 30 | ©Immunic, Inc. | 08/03/2020 IMU-838 p= 0.0002 p<0.0001 i 62% reduction Placebo 30mg/day 45 mg/day Suppression of cumulated unique active (CUA) MRI Lesions IMU-838 versus Placebo over 24 weeks Immunic
Slide 31: Conclusions Regarding Efficacy
Conclusions Regarding Efficacy = Primary and key secondary endpoints met with high statistical significance = All other secondary endpoints, including those based on other MRI parameters and on clinical endpoints such as relapse event, also provided a noticeable signal and numerical benefit for the
Slide 32: Safety
Slide 33: Overall Rate of Patients With Treatment Emergent Adverse Events
Overall Rate of Patients With Treatment Emergent Adverse Events Treatment Group Number of TEAE aceon rs 30 mg IMU-838 70 32/71 (45.1%) 45 mg IMU-838 59 28/69 (40.6%) Placebo 62 30/69 (43.5%) There were 3 patients with serious treatment-emergent adverse events (SAE) in this trial: = Placebo: Squamous
Slide 34: Reasons for Treatment Discontinuations due to Adverse Events
Reasons for Treatment Discontinuations due to Adverse Events Treatment Discontinuation Before Week 24 (all dosed patients until end of blinded treatment) Placebo 7.2% 5/69 All IMU-838 5.0% 7/140 30 mg IMU-838 4.2% 3/71 45 mg IMU-838 58% 4/69 Reasons for Treatment Discontinuation Bee | 2.6) Before We
Slide 35: Previous COMPONENT Trial of Vidofludimus
Previous COMPONENT* Trial of Vidofludimus Incidence of Liver Events!?] Liver Event TEAE Vidofludimus 35 mg Placebo By Preferred Term n=122 n=119 Biliary Colic 0 (0.0%) 1 (0.8%) Hepatic Pain 0 (0.0%) 1 (0.8%) Hepatic Steatosis 0 (0.0%) 1 (0.8%) Hepatocellular Injury 1 (0.8%) 0 (0.0%) g-Glutamyl Trans
Slide 36: EMPhASIS Trial: Detailed Assessment of Liver Events (1)
EMPhASIS Trial: Detailed Assessment of Liver Events (1): Overall Rate of Liver and Renal Events There Was No Increase in Liver or Renal Events for the Pooled IMU-838 Treatment Arms Versus Placebo During Blinded Treatment Period Treatment Group Rate of Patients With Treatment-Emergent Adverse Events
Slide 37: EMPhASIS Trial: Detailed Assessment of Liver Events (2)
EMPhASIS Trial: Detailed Assessment of Liver Events (2) Liver Enzyme Elevations Very few cases of increases of alanine aminotransferase increases (ALT) or aspartate aminotransferase (AST) above the different thresholds of upper limit of normal (ULN) * Such cases are comparable between IMU-838 treatm
Slide 38: EMPhASIS Trial: Detailed Assessment of Liver Events (3)
EMPhASIS Trial: Detailed Assessment of Liver Events (3) Hy’s Law Assessment Hy’s Law Assessment 1a-] Hyperbitirubinemia Hy’s Law Range zs ome 3 “ Sige, | 3° 3 Sc a a oa Treatment group [9 45mg ML-e3e| 6 30 mg Mus or -{ Normal range o Placebo [Sun 0.01 o4 1 Peak ALT ULN} 40 | ©immunic, inc. | 08/03/2
Slide 39: Conclusions Regarding Safety
Conclusions Regarding Safety = Consistent with prior data sets in other patient populations, administration of IMU-838 in this trial was observed to be well- tolerated, thereby also providing further evidence of a favorable safety profile of IMU-838 in the RRMS patient population. — Ingeneral, safet
Slide 40: EMPhASIS: Status Quo and Outlook
EMPhASIS: Status Quo and Outlook Available Top-Line Data Announced Today 42. | ©immunic, inc. | 08/03/2020 Analysis of the full EMPhASIS data is ongoing and is intended to be presented at the joint ACTRIMS-ECTRIMS scientific meeting on September 11 to 13, 2020 More detailed safety data (in particula
Slide 41: EMPhASIS: Summary
EMPhASIS: Summary Positive Clinical Activity Data Achieved and Unique Safety Properties of IMU-838 Further Support Potential as Best-in-Class Drug Candidate IMU-838 showed compelling clinical activity in this phase 2 trial Unique safety properties compared with current RRMS treatment options We beli
Slide 42: IMU-838 Fighting COVID-19
IMU-838 Fighting COVID-19 Leveraging DHODH’s Broad- Spectrum Antiviral Activity
Slide 43: IMU-838: Triple Attack on COVID-19
IMU-838: Triple Attack on COVID-19 IMU-838 is an advanced clinical drug candidate with attractive pharmacokinetic, safety and tolerability profile with more than 650 individuals exposed to date IMU-838 attacks COVID-19 disease by three complementary mechanisms: Inhibition of virus replication by dep
Slide 44: IMU-838: Activity Against SARS-CoV-2 and Other Viruses
IMU-838: Activity Against SARS-CoV-2 and Other Viruses oe 46 | ©Immunic, inc. | 08/03/2020 ES IMU-838 is active against SARS-CoV-2 IMU-838 has shown broad-spectrum antiviral activity against different pathogenic viruses with ECso values in single digit uM range IMU-838 SARS-CoV-2 HCV Arenavirus * Im
Slide 45: Summary of Rationale for IMU-838 in COVID-19
Summary of Rationale for IMU-838 in COVID-19 > Triple mode of action: orally available DHODH inhibitor with both, antiviral and anti-inflammatory effects plus activation of innate immune response zy Host-based mechanism: avoids dependence on specific viral proteins and, therefore, offers broad-spect
Slide 46: IMU-838: SARS-CoV-2 Preclinical Testing
IMU-838: SARS-CoV-2 Preclinical Testing Collaboration partners in Germany and the United States ma IMU-838 demonstrated inhibition @ University 9 ee ad of SARS-CoV-2 replication br. Jlender ‘AS49-ACE2 cells (human lung epithelial cells, overexpressing ACE2 receptor) fetrovroc i @ egos Virus RNA redu
Slide 47: Anticipated Pharmacokinetic Profile 22.5 mg BID
Anticipated Pharmacokinetic Profile 22.5 mg BID 14-day Treatment in Phase 2 IMU-838 in COVID-19 Patients SARS-CoV-2 25 20 Proposed dosing 15 regimen ensures that therapeutic 10 co. levels of ct IMU-838 are 5 reached starting ECso from first dose IMu-838 (uM) o 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16
Slide 48: CALVID-1: Phase 2 Clinical Trial Design in COVID-19
CALVID-1: Phase 2 Clinical Trial Design in COVID-19 Prospective, multicenter, randomized, placebo-controlled, double-blind phase 2 clinical trial Active: 2 x 22.5 mg IMU-838/day + investigator’s choice of standard-of-care therapy > Eligibl igible —> 14 days treatment patients — randomization > Contr
Slide 49: IMU-838 in Inflammatory Bowel Disease (IBD)
IMU-838 in Inflammatory Bowel Disease (IBD) New Oral Treatment Option with Promising Safety Profile
Slide 50: IBD: Therapeutic Pyramid
IBD: Therapeutic Pyramid Current solutions have limitations wo | Severe oS umab = Substantial side effects due to long-term 3 Selective = use includes increased rate of cancer risk Se Immunomodulators and virus reactivation of currently used ie} = : >| Moderate Traditional Immunomodulators immunosup
Slide 51: IMU-838: Key Strengths That Address Limitation of Existing Therapies in IBD
IMU-838: Key Strengths That Address Limitation of Existing Therapies in IBD Ts No clinical evidence of increased rate of viral re- activations — in-vitro data of direct antiviral effect Mode of action may provide a new treatment option for patients failing other therapies in IBD Small molecule with
Slide 52: ENTRANCE Study: Primary Efficacy Results
ENTRANCE Study: Primary Efficacy Results Number of Patients Cc . 9 Non- ENTRANCE Study:04] x PEE Responders Responders (11.5%) > Study performed with active 1s aeoe (34.6%) moiety vidofludimus - Y to Total Response 4 BEG All patients failed two attempts to taper down steroids omplete Responders (53.
Slide 53: CALDOSE-1: Clinical Phase 2 in UC Ongoing
CALDOSE-1: Clinical Phase 2 in UC Ongoing Coordinating investigator: Dr. Geert d’Haens (AMC Amsterdam) Active IND in the United States Overall number of patients: 240 Currently more than 65 active sites in 9 countries: USA, Western, Central and Eastern Europe wor nica gov-NcTOS3=3962 55. | ©lmmunic,
Slide 54: CALDOSE-1: Phase 2 Trial Design in UC
CALDOSE-1: Phase 2 Trial Design in UC Induction Phase Placebo (n=60) 10 mg IMU-838 qd (n=60) 30 mg IMU-838 qd (n=60) 45 mg IMU-838 qd (n=60) 10 weeks Maintenance Phase Patients with symptomatic remission at weeks 10 or 22 * Placebo (n=60) 10 mg IMU-838 qd 30 mg IMU-838 qd. Patient number required: n
Slide 55: CALDOSE-1: Interim Analysis Established Potentially Broad Effective Dose Range
CALDOSE-1: Interim Analysis Established Potentially Broad Effective Dose Range ® Performed by an unblinded data review committee (DRC) in August 2019 = Analysis based on all available clinical, endoscopic, @) aS biomarker, PD, and safety data [| Main Treatment Period The interim analysis supported t
Slide 56: IMU-838 in Primary Sclerosing Cholangitis (PSC)
IMU-838 in Primary Sclerosing Cholangitis (PSC) Investigator-Sponsored Trial Performed at the Mayo Clinic
Slide 57: IMU-838: Phase 2 Proof-of-Concept Study in PSC
IMU-838: Phase 2 Proof-of-Concept Study in PSC Rare progressive liver disease without approved pharmaceutical treatments Principal Investigator Elizabeth Carey, MD (Mayo Clinic) Investigator-Sponsored Trial in Patients with PSC Single-arm, open-label, exploratory study planning to enroll 30 patients
Slide 58: IMU-838 in PSC: Study Flow Chart
IMU-838 in PSC: Study Flow Chart Enrollment Lead-in dosing 15 mg ed 1 week ; a Inclusion Criteria Treatment Male or female subject aged 18 to 75 years 30 (6 aaa Diagnosis of PSC consistent with the guidelines published by the AASLD. ¢ All subjects must have an elevated serum ALP c of at least 1.5 ti
Slide 59: IP Position of IMU-838: Several Layers of IP
IP Position of IMU-838: Several Layers of IP @ IMU-838 is protected by several layers of patents Patent on the specific salt form and pharmaceutical composition of IMU-838, granted in the US, EU and other key markets — expires in 2031 New patent filed in 2018 on the specific polymorph of IMU-838 use
Slide 60: IMU-935
IMU-935 Unique RORyt Inverse Agonist
Slide 61: Autoimmune Diseases and IMU-935
Autoimmune Diseases and IMU-935 a - i Unmet Need in Psoriasis Care IL-17 in Autoimmune Diseases = Autoimmune diseases are frequent diseases affecting millions of patients worldwidet! = Th17/IL-17/RORyt axis is important in auto immunity related diseases!) = Antibodies targeting this axis successfull
Slide 62: IMU-935: Cytokine Inhibition in Low Nanomolar Range
IMU-935: Cytokine Inhibition in Low Nanomolar Range Effect of the development compound IM105935 (IMU-935) in stimulated human PBMCs ICs(uM) LATA 0.005 ILA7F 0.004 IFNy 0.003 IL-ta and b 1 inhibition 145,68 1 inhibition RORy (MST) 0.024 RORy (cellular, reporter assay) 0.020 DHODH 0.240 Th17 different
Slide 63: IMU-935 Maintains Normal Thymocyte Maturation and Retains Basal Activity of RORyt
IMU-935 Maintains Normal Thymocyte Maturation and Retains Basal Activity of RORyt Trymooyte ‘Normal thymocyte, No risk ‘maturation maturation for thymoma Method 50 T 0 nM/DMSO 3nM * Sorted murine DN thymocytes were cultured on OP9-DL4 40. 1m 30nM fibroblasts with mouse IL-7 for 72 hours and treated
Slide 64: IMU-935: Phase 1 Study Performed in Australia
IMU-935: Phase 1 Study Performed in Australia Y 66 | ©immunic, inc. | 08/03/2020 Double-blind, placebo-controlled clinical phase 1 study performed by Immunic subsidiary in Australia Availability of experienced early phase CROs and phase 1 units = CMAX phase 1 Unit (Adelaide/SA) = Avance Clinical CRO
Slide 65: IMU-935: Pharmacokinetic Results of Single Ascending Dose
IMU-935: Pharmacokinetic Results of Sing Cohorts 1-5 Predictable Dose-Linear Pharmacokinetics Plasma Concentration (ng/mL) Preliminary data 67 | ©immunic, Inc. | 08/03/2020 Serum half life: 24-27 hours t-max: 1.3-L8 hours cohen t~ 250mg ns) (conor 2 (Para s—Fat)—S0mg[n) (conor (Pavoa Fas) ~S0mg n=5)
Slide 66: IMU-935: Pharmacokinetic Modeling of Multiple Dose
IMU-935: Pharmacokinetic Modeling of Multiple Dose >| sm 100 Prediction of multiple a Aarti gm ReROUeneueguan dose pharmacokinetics 3 | | ine ! F f reams ETAT TTL Estimated accumulation § | factor for multiple 4900 dosing 1.22 2090 ICypll-17, IFNy wee eee and TI iff, om sooo ammo Samm == amma Time (
Slide 67: IMU-856
IMU-856 Restoring Intestinal Barrier Function
Slide 68: Concept of IMU-856: Restoring the Intestinal Barrier Function
Concept of IMU-856: Restoring the Intestinal Barrier Function Without Impairing the Immune System Picture taken from hips //ibrantblueis.com/essentia-oi-o-healand-seatthe gut! 70 | ©immunic, Inc. | 08/03/2020
Slide 69: IMU-856's Target: An Epigenetic Regulator
IMU-856’s Target: An Epigenetic Regulator... .. influencing the tightly regulated network of genes and proteins associated with epithelial cell interaction/adhesion through its enzyme activities. Target Gene expression Cellular functions @ Protein function Protein activity 71 | ©immunic, inc. | 08/0
Slide 70: IMU-856: Hypothesis of Therapeutic Approach
IMU-856: Hypothesis of Therapeutic Approach Compartmentalize microbiome and immune system By strengthening the bowel barrier function Microbiota Immune system Sod Focus on immunosuppression Influencing the microbiome = Changes in nutrition are driving the increase in disease rates * Stimulation of t
Slide 71: IMU-856: Development Concept
IMU-856: Development Concept Option and licensing agreement with Daiichi Sankyo, option exercised in January 2020 = |mmunic obtained exclusive rights to commercialization of IMU-856 in all countries, including the United States, Europe and Japan Finalize preclinical work Phase 1 study expected H1/20
Slide 72: Immunic Therapeutics Summary
Immunic Therapeutics Summary
Slide 73: Summary
iti\ IMU-838 met all statistical endpoints and underlines favorable safety and tolerability profile Several clinical phase 2 trials with IMU-838 expected to read-out in the next couple of months 75 | ©mmunic, inc. | 08/03/2020 Shares outstandin (as of June 30, 2020) Cash and cash equivalents of (as
Slide 74: Thank You!
Thank You! Immunic AG N Immunic, Inc. Grafelfing near Munich 1200 Avenue of the Americas Germany | New York City, NY 10036 = y/ USA 7 Immunic Research GmbH Weinberg Campus Halle (Saale) Germany Immunic Australia Pty. Ltd. “Melbourne Australia 76 | ©immunic, inc. | 08/03/2020 Immunic
Slide 75: Immunic, Inc.
Immunic, Inc. 1200 Ave of the Americas, Suite 200 Head of IR & Communications Blew Norke NY 00363050. Phone: +49 89 2080 477 09 ® www.imux.com Email: ir@imux.com 7 | @ mmc ne. | e503/2000 © Immunic